ArticleScientific reports2026
Discovery of small molecule inhibitors of liver X receptor for pediatric metabolic disorders by structure based screening, modelling, dft analysis and MD simulation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic disorders such as dyslipidemia and cholesterol-related diseases in pediatric populations have become a major concern, highlighting the need for effective therapeutic strategies. Liver X Receptor (LXR) is one of the key factors that control lipid metabolism and can be used as the treatment target. The aim of this study was to discover possible LXR inhibitors to use in pediatric metabolic disorders through an in-silico method, which combines molecular modeling, quantum chemical analysis, and molecular dynamics simulations. Molecular docking was performed to screen compounds from the ChEMBL database and quantum chemical analysis to determine electronic properties of the screened compounds. MD simulations over 100 ns confirmed the stability of the protein-ligand complex, supported by consistent RMSD, RMSF, and hydrogen bonding profiles. DFT analysis further indicated suitable electronic properties for receptor interaction. ADMET predictions suggested favorable pharmacokinetic and toxicity profiles. However, experimental validation is required to confirm the biological activity and therapeutic potential of the identified compounds. This study provides a computational framework for the discovery of LXR inhibitors targeting pediatric metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.